Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
about
Tuberculosis vaccines: beyond bacille Calmette-GuerinHost immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosisVaccines against tuberculosis: where are we and where do we need to go?Prime-boost approaches to tuberculosis vaccine developmentProspects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?Mycobacterium bovis Infection of Cattle and White-Tailed Deer: Translational Research of Relevance to Human TuberculosisCurrent efforts and future prospects in the development of live mycobacteria as vaccinesImproving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cellsPriming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cellsSimultaneous immunization against tuberculosisA review of the literature on the economics of vaccination against TB.Toward novel vaccines against tuberculosis: current hopes and obstacles.Protective efficacy of BCG overexpressing an L,D-transpeptidase against M. tuberculosis infection.The immunology of tuberculosis: from bench to bedside.Novel vaccination approaches to prevent tuberculosis in childrenNovel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaquesDual neonate vaccine platform against HIV-1 and M. tuberculosis.Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.rBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B.Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in miceRecombinant BCG as a vaccine vehicle to protect against tuberculosis.Development of new vaccines and drugs for TB: limitations and potential strategic errorsRelief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens.Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells.Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosisA recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis.Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety ConsiderationsImproving the Immunogenicity of the Mycobacterium bovis BCG Vaccine by Non-Genetic Bacterial Surface Decoration Using the Avidin-Biotin SystemNonclinical Development of BCG Replacement Vaccine Candidates.Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease ControlA Modified Bacillus Calmette-Guérin (BCG) Vaccine with Reduced Activity of Antioxidants and Glutamine Synthetase Exhibits Enhanced Protection of Mice despite Diminished in Vivo Persistence.Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis.Prime-boost vaccination with rBCG/rAd35 enhances CD8⁺ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates.Urease activity represents an alternative pathway for Mycobacterium tuberculosis nitrogen metabolism.Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine EfficacyProtection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.Antituberculous vaccine development: a perspective for the endemic world.
P2860
Q22242669-D827418B-C315-4A32-93A6-10CECAA18CE9Q26863391-480F88F1-B8C6-4CEF-A0E7-6128580E13A4Q26992233-60D94EDF-E8A2-48E0-B4DB-20C053CEC3C6Q27024526-803DB8E1-D048-4CF1-9221-F29B44EE3A47Q28083377-1F83AF0E-079F-413A-9747-56C6A4053A8EQ28083909-CBB2852C-A6A0-4726-ADB3-8ECCCE66141CQ28087077-4BFE3203-6FCB-4B61-BBF2-94FF8C2EC2CAQ28543248-C67EE56B-7CA2-4052-83E8-09ACADA21A33Q28730854-D18C5616-8EC1-4483-9A6E-F104FE1748E6Q28742666-17FE010D-9911-4559-A05D-AD174626C1B0Q30413692-2EAA8804-F15A-4927-8D9D-962FD9D8E3E8Q30484783-DA4D1469-0FAE-462B-BE9E-0919514EC004Q33737428-59068E30-198D-4DB5-9E7B-437130133697Q33777367-0AE511A6-5C1F-4809-BCB0-7CD174F1CA7BQ33801426-937D42D5-76B6-4E3F-AE5E-CE28C4D991F5Q33877458-86CF926D-8F89-48E6-8CA5-3285694CF852Q33908584-DB3149B4-6DA7-4243-A616-D55B66451797Q33992101-FC181D62-D441-41B5-9FD3-BD24062428BAQ34290885-AE76F3DF-A8D5-4263-B3F3-42706EB2A000Q34298426-916AA52D-E757-4C51-AD52-4026BBEAC9B9Q34309667-CAD0FB3A-046C-49E4-A574-54CFA62AB0E4Q34518560-93DFF2C4-2708-4E6E-B1B4-5BE4051669BEQ35065531-0156D82B-CE8B-49FC-8585-DF3C186D85F3Q35066463-8B655A7A-E2A5-4B48-999B-89AD52C78FA6Q35191136-CCA6DD78-4369-4D17-915E-C3D4BA68E22BQ35211139-84813E2C-F591-4AEE-898C-D47E404A5A71Q35647253-40FC8D13-5618-4DA0-8FE6-43AB99F63760Q35782951-043F8C08-7EF6-4320-ABF5-B84AF3BF1039Q35826779-1A4FFF65-7BB5-43EB-BC7B-55F4287D7E9DQ35881624-AA49B690-109C-4D67-A727-0890F22DE0FFQ35890636-0A987DC8-1AB4-486E-8711-C4F38D81D442Q35909944-91AD2438-44B7-4C42-8D57-67A267898048Q36003382-56F63F35-2035-4BDC-87B3-29C8130EA04AQ36038717-66AAC82F-6026-4D0C-A67B-D4812377E447Q36071705-89BA6F88-40FC-479B-975F-6923286CAE1CQ36211121-BB44A90F-B026-405A-A044-BBAA15A5E8C6Q36219941-9EAC6307-3FA5-471B-8B59-C26B12192D23Q36555077-10A5D9FB-CFBA-4841-9977-FB72EE2E2D5AQ37008729-BF04320F-9AC7-483F-B8E5-EACFE43F759FQ37622900-5CA6FDED-CA89-4CFE-9145-8A1162886735
P2860
Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Novel recombinant BCG expressi ...... th Mycobacterium tuberculosis.
@en
Novel recombinant BCG expressi ...... th Mycobacterium tuberculosis.
@nl
type
label
Novel recombinant BCG expressi ...... th Mycobacterium tuberculosis.
@en
Novel recombinant BCG expressi ...... th Mycobacterium tuberculosis.
@nl
prefLabel
Novel recombinant BCG expressi ...... th Mycobacterium tuberculosis.
@en
Novel recombinant BCG expressi ...... th Mycobacterium tuberculosis.
@nl
P2093
P1433
P1476
Novel recombinant BCG expressi ...... th Mycobacterium tuberculosis.
@en
P2093
Ajay Grover
Angelo Izzo
Charles Scanga
David M Hone
Erica Penn
Jerald C Sadoff
John Fulkerson
Katherine Stagliano
Marcus A Horwitz
Ronggai Sun
P304
P356
10.1016/J.VACCINE.2009.05.048
P407
P577
2009-06-02T00:00:00Z